Skip to main content
Equibles
AMRX logo

AMRX · Amneal Pharmaceuticals, Inc. · Debt

Track AMRX — free

Use AMRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AMRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$20.20 +0.36 (+1.81%) At close · Oct 21
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$6.45B
Shares
319.35M
Volume · Oct 21 4.66M Avg daily vol (3M) 2.56M

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Long-term debt, including current maturities 2026-06-30 USD 2,570,296,000 10-Q filed 2026-08-06
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current portion of line of credit borrowings
USD 100,000,000
Current portion of long-term debt
USD 5,961,000
Noncurrent debt carrying amount
USD 2,564,335,000
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Key facts CIK 1723128 CUSIP 03168L105 13F (30d) 54 filings 50 filers Visit website Investor relations